Home >

Welcome to ASCO Connection Discussion

The ASCO Connection Discussion forum is a space for oncology professionals and others with an interest in cancer care to ask and answer questions about every aspect of the field, from professional development advice to clinical conundrums. Everyone is welcome to participate: to ask a question or leave a response, first log in with your ASCO username and password. Please read the Discussion and Commenting Guidelines before you post a question or response. Contact our staff by email for assistance with the Discussion forum.

LOGIN TO START A DISCUSSION
Filter by All Topics
International
ASCO International Affairs
Feb 22, 2017 12:01 PM
In 2015, ASCO partnered with local organizers to hold Multidisciplinary Cancer Management Courses (MCMCs) in Brazil, Zimbabwe, and China. One year later, follow-up surveys were sent to participants to assess the impact the course had on their practices.
The first MCMC was held in São Paulo, Brazil...
Molecular Oncology Tumor Board
ASCO University
Feb 15, 2017 8:30 AM
Read more to answer the following questions:
1.    Recognize the diagnosis of CML and importance of bone marrow biopsy at presentation.
2.    Apply considerations when choosing initial therapy.
3.    Recognize when to switch therapy when response is suboptimal.
4.    Identify how to treat...
International
ASCO International Affairs
Feb 08, 2017 12:45 PM
In the fall of 2015, ASCO partnered with local organizers to hold International Palliative Care Workshops (IPCW) in Morocco and Nepal. One year later, follow-up surveys were sent to participants to assess the impact the course had on their practices.
The first IPCW was held in Fez, Morocco in...
Research and Meeting News
Virginia D. Anderson
Jan 24, 2017 1:16 PM
The Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research is now accepting applications for its 2017 class of scholars. Sponsored by the Neurofibromatosis Therapeutic Acceleration Program at Johns Hopkins University, the Program works to create a community of...
Molecular Oncology Tumor Board
ASCO University
Jan 11, 2017 2:00 PM
Read more to answer the following questions: 1) Which tests are the most appropriate in identifying a BRAF codon 600 mutation for potential FDA-targeted treatment? 2) What is the significance of the CDKN2A mutation? 3) If systemic therapy is selected, would you be more inclined to offer targeted...

Pages